Indiana University Health Melvin and Bren Simon Cancer Center

Indianapolis, Indiana 46202

1 studies enrolling now · 41 studies all time

What they study most

Advanced Biliary Tract Cancer, Advanced or Metastatic Melanoma, Advanced or Recurrent Solid Tumors, Advanced, Androgen Receptor Positive Triple Negative Breast Cancer, Arthralgia, B Cells--Tumors, B-cell Lymphoma, BRAF V600E-mutant Metastatic Colorectal Cancer, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Brain Metastases, Breast Cancer

Studies at this site

• A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) — Recruiting now
• DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma — Recruiting now
• The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer — Running, not enrolling
• Circulating Tumor Cells (CTC) in Lung Cancer — Running, not enrolling
• A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer — Running, not enrolling
• T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) — Completed
• NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer — Running, not enrolling
• Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region — Completed
• A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD — Completed
• Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer — Completed
• PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC — Completed
• Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer — Completed
• Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases — Stopped early
• Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies — Completed
• A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile — Stopped early
• Pre-Operative Radiation and Veliparib for Breast Cancer — Completed
• Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer — Completed
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile — Stopped early
• Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma — Stopped early
• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen — Completed
• Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma — Completed
• Open-Label Extension and Safety Study of Talazoparib — Completed
• Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies — Completed
• BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) — Completed
• Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer — Stopped early
• Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation — Completed
• Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy — Completed
• Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) — Completed
• Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation — Completed
• Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor — Completed
• Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer — Completed
• Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma — Completed
• iMETX (Individualized Metabolic RX): a Pilot Study — Completed
• Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors — Stopped early
• A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) — Stopped early
• Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors — Completed
• Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias — Withdrawn before enrolling
• Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse — Completed
• Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML — Stopped early
• Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma — Completed